Genome Institute of Singapore
Dr. DasGupta is a Senior Group Leader at the Genome Institute of Singapore (Precision Oncology program), and holds an adjunct Associate Professor position at CSI-NUS. He also holds an adjunct Associate Professor position at the New York University Cancer Institute, New York. The overall research goal is to define the impact of intra-tumor heterogeneity (ITH) and the tumor microenvironment (TME) on tumor evolution during the emergence of treatment resistant and metastatic disease. A wide variety of functional genomic approaches are employed including single-cell/bulk transcriptomics, epigenomics, and exome-seq to address questions related to how individual cells evolve/acquire metastatic and resistant phenotypes. The DasGupta lab has also initiated a major program in “phenotype-driven precision oncology” by establishing the next-generation of HTS-amenable patient-personalized cancer models to identify novel therapeutic opportunities, and novel, gene expression-based biomarkers that can be used for patient stratification. In addition, the DasGupta lab is also interested in the identification and functional characterization of non-coding RNAs (ncRNAs), and associated RNA-binding proteins (RNPs) in the regulation of oncogenic signaling pathways.